ArticleOpen life sciences2025
Creutzfeldt-Jakob disease mimicking Hashimoto's encephalopathy: steroid response followed by decline.
Article in Open life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis of Creutzfeldt-Jakob disease (CJD) is particularly challenging because its heterogeneous clinical presentations mimic other rapidly progressive dementias and neurodegenerative disorders (e.g., Hashimoto's encephalopathy, autoimmune encephalitis, atypical Alzheimer's disease). Diffusion-weighted imaging (DWI) is the most sensitive neuroimaging sequence for diagnosing CJD. However, early magnetic resonance imaging (MRI) findings may be subtle or evolving, and autoimmune etiologies often remain in the differential. Therefore, empiric corticosteroids are reserved for cases in which an autoimmune etiology is under consideration while definitive tests are pending. A 67-year-old woman presented with rapidly progressive cognitive decline, ataxia, and visual symptoms. Short-course glucocorticoids produced transient improvement for three days, followed by rapid deterioration within a week. Serial MRI evolved from cortical ribboning to basal ganglia involvement. Electroencephalogram (EEG) showed non-convulsive status epilepticus that responded to diazepam and valproate. Cerebrospinal fluid (CSF) 14-3-3 protein (14-3-3) and RT-QuIC were positive, confirming prion disease. CJD can present with features resembling HE, and brief improvement after a short course of glucocorticoids, even in the presence of markedly elevated thyroid antibodies, does not exclude CJD. To avoid diagnostic delay, obtain CSF RT-QuIC and 14-3-3 at presentation before or in parallel with glucocorticoids, and use serial MRI and EEG to arbitrate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.